Related Experiment Videos
Mitomycin-C in the treatment of tracheal cicatrix after tracheal reconstruction
1Department of Otolaryngology, Cornell University Medical College, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA. Ward10021@aol.com
Insights
Mitomycin-C (MMC) shows promise for treating difficult tracheal stenosis in children. Topical MMC application aided in decannulation for five pediatric patients with recurrent tracheal issues.
Area of Science:
- Pulmonary Medicine
- Surgical Innovation
- Pediatric Airway Management
Background:
- Tracheal stenosis is a challenging condition, often recurring after surgical reconstruction.
- Current treatments for severe, recurrent tracheal stenosis have limitations.
- Mitomycin-C (MMC), an antifibrotic agent, is effective in other surgical applications.
Observation:
- A case series reviewed five pediatric patients with severe, recurrent tracheal stenosis.
- Patients underwent topical MMC application (0.1 mg/ml for 2 min) during bronchoscopy and laser treatment.
- MMC was applied to lysed cicatrix tissue intraoperatively.
Findings:
- All five pediatric patients treated with topical MMC were successfully decannulated.
- This preliminary study suggests MMC can help manage recurrent tracheal granulation and cicatrix.
- The mechanism of action involves inhibiting fibroblast proliferation.
Implications:
- Topical Mitomycin-C may offer a new therapeutic option for pediatric tracheal stenosis.
- Further research is warranted to confirm efficacy and optimize MMC use in airway surgery.
- This approach could improve outcomes for children with complex airway problems.
Objective:
To demonstrate the potential use of Mitomycin-C (MMC) in the treatment of difficult and recurrent tracheal stenosis.
Design:
Case series.
Setting:
Tertiary care setting.
Patients:
A retrospective chart review was performed on five pediatric patients with severe, recurrent tracheal granulation and cicatrix after tracheal reconstruction who were treated with topical MMC as an adjunct to bronchoscopy and laser treatment. MMC was applied intraoperatively on saturated pledgets at a dose of 0.1 mg/ml for 2 min to the area where the cicatrix had been lysed. The five patients were able to be decannulated.
Discussion:
Mitomycin-C is an anti metabolite known to inhibit fibroblast proliferation in vitro. This agent has been used with a high success rate in glaucoma filtration surgery to promote patency of the trabecula. The results of this preliminary application in the pediatric airway as well as the mechanism of action will be discussed.